The FDA has approved Eli Lilly's oral SERD Inluriyo in combination with its cancer drug Verzenio, according to Fierce Pharma. The approval adds a new combination option in the oral SERD space and intensifies the competitive landscape in that drug class.
The approval follows data showing the combination delivered longer progression-free survival than oral SERD monotherapy. Jake Van Naarden, president of Lilly Oncology, told Fierce Pharma he expects most patients to select the combination over single-agent treatment.
Because this article draws on a single source, there is no conflicting account to compare. The reported outcome and the company's expectation are presented as stated in Fierce Pharma's coverage.